To develop an animal model for sickle cell anemia, we have created transgenic mice that express a severe naturally occurring human sickling hemoglobin, Hb S Antilles. Due to its low solubility and oxygen affinity, Hb S Antilles has a greater propensity to cause red cell sickling than Hb S. To make transgenic animals that express a high level of Hb S Antilles, the erythroid-specific DNAse I hypersensitive site II from the human fl-globin cluster was linked independently to the human a 2-globin gene and to the fis gene. Embryos were injected with both constructs simultaneously and seven transgenic mice were obtained, three of which contained both the human a and the human fis =i'j transgene. After crossing the human transgenes into the mouse jl-thalassemic background a transgenic mouse line was derived in which approximately half the fl-globin chains in the murine red cells were human fls '". Deoxygenation of the transgenic red cells in vitro resulted in extensive sickling. An increase of in vivo sickling was achieved by placing these transgenic mice in a low oxygen environment. This murine model for red cell sickling should help to advance our understanding of sickle cell disease and may provide a model to test therapeutic interventions. (J. Clin. Invest. 1991. 87:639-647.)
Introduction
A transgenic mouse model for sickle cell anemia would be valuable in the analysis of factors that initiate red cell sickling in the whole organism, in the study of the pathophysiological consequences of sickling, and in the development of experimental approaches for treatment. Prior attempts at creating such a model have included the introduction of the human ,-( 1) and both the human a-and #3-globin genes (2, 3) into the mouse genome. The transgenic mouse with the highest levels of Hb S in its red cells (> 80% of red cell hemoglobin was Hb S) was described by Greaves et al. (2) . Although complete deoxygenation resulted in 100% of red cells from this animal to sickle in vitro, only 0.1% of red cells sickled in vivo. Analysis of the animal revealed normal somatic development, no obvious manifestations of disease, and no evidence of hemolytic ane-exhibit signs of significant in vivo sickling, taken in conjunction with prior analyses ofthe mechanism regulating hemoglobin polymerization, suggests that criteria for significant in vivo sickling to occur may need to include the following: (a) that the pathological sickling hemoglobin molecules be present at sufficiently high levels or have sufficiently low solubility such that polymerization and sickling will occur in the presence of murine hemoglobin (1, 4) , and (b) that the human hemoglobin have an oxygen affinity that will favor its existence in the deoxygenated form in murine red cells.
Hemoglobin S Antilles (Hb S Antilles)' is a human sickling variant that, unlike Hb S, results in significant red cell sickling, anemia, and vaso occlusion in heterozygote carriers (A/S Antilles) (5) . Erythrocytes of carriers of the Hb A/S Antilles trait sickle at an oxygen partial pressure similar to that which induces sickling in Hb S/C disease. The Os A"tJIJC-globin chain of the Hb S Antilles molecule contains two mutations, Glu6 -* Val6 (the f3-chain mutation responsible for sickle cell anemia) and Val23 -) Ie23 (5) . These two mutations result in the decreased solubility and lower oxygen affinity of Hb S Antilles compared with Hb S. (For purified Hb S Antilles and Hb S the minimal gelling concentration is I1 g/dl and 18.4 g/dl, and the P50 is 9 mmHg and 5.5 mmHg, respectively.) Red cells oftransgenic mice expressing high levels of human globin transgenes also contain highly soluble murine hemoglobin (7) (8) (9) . The oxygen affinity of the murine hemoglobin is significantly lower than that of Hb S but not that of Hb S Antilles (6) . These observations suggest that Hb S Antilles may be a better candidate for producing in vivo red cell sickling in transgenic mice than Hb S.
Several studies have indicated that dominant control regions containing erythroid specific DNase I hypersensitive sites that flank the human f,-globin cluster play a pivotal role in determining the level ofexpression ofglobin genes in erythroid cells (7) (8) (9) (10) (11) (12) . The ability to link these erythroid dominant control regions to globin genes in transgenic mice has enabled several investigators to achieve high level expression of human globin genes in mouse red cells. Recently Globin chain analysis. The globin chains and their tryptic fragments were separated by reverse-phase HPLC. Hemoglobin was run on a C-4 (I X 25 cm, 300 A pore, 5-jim particle size) column (Vydac, Hesperia, CA) at a flow rate of 1.7 ml/min. A modified nonlinear gradient was used to develop the column (21) . Tryptic fragments were prepared from the isolated human globin chains and separated by reverse-phase HPLC (22) . Evaporated HPLC fractions were analyzed in a glycerol:thioglycerol (1:1) 0.1 N HCI matrix by liquid secondary ion mass spectrometry on a VG 30-250 quadrupole mass spectrometer (VG Biotech Ltd., Altrincham, UK). The average molecular mass analysis of the intact human a-and (S AntilleS-globin chains was determined by electrospray mass spectrometry (23) on a VG Bio-Q mass spectrometer. Mouse globin chains were identified by Triton urea gel electrophoresis of isolated globin chains (24) particle size) (Toyo Soda Manufacturing Co., Ltd., Tokyo, Japan). The composition ofeach hemoglobin species was determined by first isolating the hemoglobin and then determining its globin chain composition by reverse phase HPLC.
Deoxygenation ofred cells. Deoxygenation was performed by blowing humidified nitrogen through a test tube containing 10 jd of fresh mouse blood in 1 ml of PBS at 4VC for 40 min. The sealed deoxygenated sample was then placed at 370C for 40 min followed by fixation with 100 ,l of a deoxygenated 1.5% glutaraldehyde solution. Reoxygenation involved uncapping the sealed deoxygenated tube just before fixation, swirling the sample to promote contact with air for 5 min, and then adding the glutaraldehyde fixative.
Analysis ofmice subjected to hypoxia. Transgenic and control mice were placed in a hypobaric chamber for confirmed by the appropriate hybridization of these clones to oligonucleotide probes specific for the two mutations that distinguish the mutant 3s Antlles allele from the normal ,B-globin allele (Fig. 1) .
The human a and fls 'n globin gene constructs that were coinjected into fertilized mouse eggs are shown in Fig. 2 (Table I) and the a to a ratio (Table II) of transgenic/fl-thalassemic mice indicates that expression of the human transgenes corrects the inherent globin chain imbalance and associated anemia of homozygous /-thalassemic mice. These results are consistent with a previous study in which /3-globin transgenes alone corrected the thalassemic phenotype when introduced into the homozygous /-thalassemic mouse background (29).
The globin chains in red cells from the transgenic//-thalassemic animals were separated by reverse-phase HPLC (Fig. 4) . 5a-human a-globin chain comprises 17% of the total a-globin chains in red cells from transgenic/fl-thalassemic mice. This is a significant increase over the human /s Antilles-globin chain (14%) and a-globin chain (9%) levels of the founder animal 58 (Table II) . The relative increase of /S Antilles compared with human a-globin chains after transfer of the human transgenes into the /3-thalassemic background may be related to the previously demonstrated increased translational efficiency of /-versus a-globin mRNA in murine /3-thalassemic red cells (30) .
Identification of the human globin chains separated by reverse-phase HPLC was confirmed by preparing tryptic digests of the isolated chains, separating the resulting tryptic peptides and determining their masses by liquid secondary ion mass spectrometry (22) . Tryptic digestion of the OS3 Antillesglobin chain isolated from the transgenic mouse red cells resulted in two peptides that differed in molecular mass from their normal human /-globin chain counterparts (Fig. 5) . Tryptic peptide 1 (T 1) with a protonated molecular ion mass of 922 D matches the predicted mass ofthe human /3-globin chain tryptic peptide T 1 but with a valine instead of a glutamic acid at position 6. Tryptic peptide 3 (T3) with a protonated molecular ion mass of 1,328 D matches the predicted mass of the human /3-globin chain tryptic peptide T3 but with an isoleucine instead of a valine at position 23 . The second tryptic peptide in Fig. 5 The hemoglobins present in transgenic/fl-thalassemic red cells were separated by ion exchange HPLC (Fig. 6) . The hybrid mouse a/human fls A"ntils hemoglobin (40%) along with authentic mouse hemoglobin (46%) are the two predominant hemoglobin species (Table II) . The minor hemoglobin species present in these red cells include authentic human Hb S Antilles (8%), and a hybrid human a/mouse #3 hemoglobin (6%). Red cells from the founder animal 58 have a similar level ofauthentic Hb S Antilles (6%) but a reduced level of hybrid mouse a/human f3s Al hemoglobin (8%) compared with cells from transgenic/f3-thalassemic mice (Table II) .
Cellular properties. Classical morphologic sickling was observed after deoxygenation in vitro in -30% ofthe transgenic/ fl-thalassemic red cells, while the remaining cells exhibited varying degrees of shape abnormalities (Fig. 7, a and b) . These morphological changes were reversed by reoxygenation of the sample (Fig. 7, c and d) . Deoxygenation of nontransgenic thalassemic red cells or red cells from normal mice did not result in sickling or morphological changes (data not shown).
The possibility of in vivo sickling was suggested by the appearance ofoccasional irreversibly sickled cells (ISCs) in peripheral blood smears. To determine if hypoxia would increase the number of sickled cells formed in vivo we placed the transgenic/f3-thalassemic animals in an hypoxic environment. Since a discernible effect of hypoxia on sickling red cells is a change in cell volume, we quantitated cell volume distribution before and after the hypoxic exposure. The volume ofsickled red cells is altered following repeated cycles of hemoglobin polymerization, and red cells from individuals with sickle cell disease exhibit a broader than normal volume distribution. This is believed to be the result of an increased number of cells with smaller volumes due to dehydration and larger volumes due to stress erythropoiesis (26) .
The volume distribution of red cells from the transgenic and control animals are similar at an ambient FiO2 of20% (Fig.   8 ). The normal volume distribution curves of red cells from transgenic/fl-thalassemic mice are in agreement with the normalization of the hematological indices (Table I) and the a/,8 ratio (Table II) found in the dense cell fraction of red cells from humans with sickle cell anemia (32) . To examine red cells from hypoxic transgenic mice with decreased volume and increased density, we isolated dense cells from four transgenic and four control animals using a Stractan gradient. Several typical fields of dense cells from a transgenic animal after hypoxic exposure are shown in Fig. 9 . Consistent with the volume distribution curves, nearly every field of dense red cells from the hypoxic transgenic mice contains several ISCs while, before the hypoxic exposure, the most dense fraction of red cells from these transgenic mice had very few ISCs. No ISCs were seen in control mice before or after hypoxic exposure.
Discussion
In this study we have created transgenic mice containing hu- The hemoglobins present in the red cells of the transgenic mice in this study were characterized using the combination of ion exchange HPLC, which separates all the hemoglobin species present in these red cells, followed by reverse-phase HPLC to identify the globin chain composition of each hemoglobin. The predominance of the hybrid mouse a/human As Antilles hemoglobin in sickling transgenic red cells suggests that this molecule may be participating in hemoglobin polymerization. This is further supported by the observation that both in vitro and in vivo sickling occurs in transgenic/fl-thalassemic red cells containing 8% Hb S Antilles and 40% hybrid mouse a/human Antilles hemoglobin, but does not occur in red cells of the 58 founder animal that contain a similar amount of Hb S Antilles (6%) but significantly less of the hybrid mouse a/human 3SAnftilles hemoglobin molecule (8%). Prior in vitro analyses of the kinetics of polymerization of hybrid mouse a/human f3s
Anfltil as well as hybrid mouse a/human f3s hemoglobin suggested that these mouse/human hybrids would not polymerize (6) . However, it should be noted that the Hb concentrations used in these earlier studies were 250-fold lower than that found in red cells. This could explain the discrepancy between our findings with intact red cells and the previous solution assays. In The ability to detect and quantitate red cell changes in response to hypoxia in transgenic mice may provide new opportunities for examining red cell sickling in vivo. This system could be used to perform studies that are difficult to do in humans, such as examining the efficacy of experimental antisickling agents. In spite of differences between Hb S and Hb S Antilles, the need for an animal model for sickle cell anemia, the lack of which has long hindered the study of this disease, may in part be met by this transgenic mouse model.
